Kelli Woltemath, DO
Family Medicine · Hamburg, IANPI 1285606731
Payments from drug & device makers
Across 51 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$234
- Mylan Specialty L.p.$208
- GSK$161
- Novo Nordisk$160
- Welch Allyn$136
- Johnson & Johnson$110
- plus $286 from 10 others
What the payments were for
- Speaking & faculty fees$16112%
- Food & beverage$76359%
- Other$37029%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 2 | $234 |
| Mylan Specialty L.p. | 12 | $208 |
| GSK | 1 | $161 |
| Novo Nordisk | 10 | $160 |
| Welch Allyn | 1 | $136 |
| Johnson & Johnson | 8 | $110 |
| Bayer | 4 | $70 |
| AbbVie | 3 | $50 |
| Pfizer | 2 | $40 |
| Lilly USA, LLC | 2 | $34 |
| Abbott | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,295 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 90 | $92,350 |
| EliquisApixaban | 101 | $63,724 |
| TrulicityDulaglutide | 54 | $52,057 |
| XareltoRivaroxaban | 58 | $50,075 |
| FarxigaDapagliflozin Propanediol | 72 | $45,508 |
| OzempicSemaglutide | 37 | $45,396 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $40,386 |
| XifaxanRifaximin | 11 | $34,065 |
| WegovySemaglutide | 25 | $33,498 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $32,333 |
| MyrbetriqMirabegron | 56 | $29,883 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $27,864 |
| JardianceEmpagliflozin | 26 | $26,026 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $25,530 |
| JanuviaSitagliptin Phosphate | 37 | $25,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $34 | $144,406144 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $160 | $100,75577 claims |
| GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta | $161 | $85,727137 claims |
| PfizerEliquis | $40 | $63,724101 claims |
| Johnson & JohnsonXarelto | $110 | $50,07558 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $14 | $44,14759 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $13 | $34,06511 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $29,88356 claims |
| AbbVieSynthroid | $50 | $2,46426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Hamburg
- Nicholas GoetschWaterloo$4.1M
- James PoockWaterloo$1.5M
- Jennifer KayCouncil Bluffs$613K
- Nicholas BechtoldSioux City$584K
- Kirk PetersonHuxley$576K
- Stephen HarrisonClinton$249K
- Sharon SteenBelle Plaine$241K
- Carlos Alarcon SchroderJohnston$237K
- Thomas RossDes Moines$170K
- Yogesh ShahDes Moines$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.